You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY20 is not expected to be complete until September, 2021.

  1. Novel Dental Adhesives to Prevent Recurrent Caries

    SBC: CuRE Innovations, LLC            Topic: NIDCR

    DESCRIPTION provided by applicant Bacterial related marginal decay is the top reason for failure and retreatment of resin based composite restorations RBCs Retreatment of these restorations costs both the patients and insurance companies billions of dollars per year The weak point of the system is the zone known as the hybrid layer where the adhesive bonds the RBC to the dentin There are ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  2. Development of nucleic acid delivery platform based on polymeric CXCR4 antagonists

    SBC: Bohemica Pharmaceuticals, LLC            Topic: 100

    DESCRIPTION provided by applicant Therapeutics based on nucleic acids NA promise to revolutionize treatment of multiple diseases but their widespread use is currently limited by the lack of efficient delivery methods We have recently developed a new NA delivery platform based on polymeric CXCR inhibitors PCX suitable as dual function systems for simultaneous NA delivery and inhibition of ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  3. Novel mechanism for the treatment of epilepsy: New Vitamin K analogs target energetics and have low toxicity due to excellent specificity and low dose requirements compared to current therapies

    SBC: Neuroene Therapeutics, LLC            Topic: 106

    DESCRIPTION provided by applicant Epilepsy is the th most common neurological disorder with in people developing epilepsy the occurrence of more than one unprovoked seizure at some point in their lifetime Unfortunately of all patients have intractable medication resistant epilepsy Thus new anti epileptic drugs AEDs that target alternative mechanisms of action are needed ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  4. Mutation Enriched Targeted Re Sequencing

    SBC: TRANSGENOMIC, INC.            Topic: 103

    DESCRIPTION provided by applicant Low level tumor associated somatic DNA mutations can have profound implications for development of metastasis prognosis choice of treatment follow up or early cancer detection Unless they are effectively detected these low level mutations can misinform patient management decisions or become missed opportunities for personalized medicine Widely used tech ...

    STTR Phase II 2016 Department of Health and Human ServicesNational Institutes of Health
  5. Aminoglycosides with reduced ototoxicity

    SBC: NUBAD, LLC            Topic: NIAID

    PROJECT SUMMARY Aminoglycosides are one of the cheapest and well known antibiotics in clinical use for over years but one of the major limitations in their use is their ototoxicity We are developing fast and low cost methods to develop aminoglycosides with anti ribosomal activities and reduced toxicity In this project we will identify novel aminoglycoside antibacterials that show reduced ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  6. Novel small-molecule targeted therapy for prostate cancer

    SBC: MetCure Therapeutics LLC            Topic: 102

    Enzalutamide resistance is a major obstacle in the treatment of metastatic castration resistant prostate cancer mCRPC Recently we developed a small molecule lead compound BKM and demonstrated its potent activity against bone metastatic prostate cancer cells In this Phase I STTR application we hypothesize that BKM is a novel targeted therapy to overcome enzalutamide resistance and eff ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  7. Screening the Ribosome for New Target Sites

    SBC: NUBAD, LLC            Topic: NIAID

    DESCRIPTION provided by applicant Nucleic acids are avenues for drug design both as therapeutics and as targets Here we propose to establish new methods for identifying antibiotic ribosome targets and lead compounds Targeting specific RNA such as rRNA which are involved in proliferation and survival of bacteria is a promising approach We are developing fast and low cost methods to screen s ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  8. Molecular Imaging of Early Stage of Liver Fibrosis by Novel Protein Agents

    SBC: INLIGHTA BIOSCIENCES L.L.C.            Topic: NIAAA

    Abstract Liver fibrosis cirrhosis is one of the most common outcomes of chronic liver disease Chronic liver disease is assessed by progressive fibrosis caused by repeated injury due to metabolic dysfunction alcohol abuse viral hepatitis or autoimmune disease If it is left unchecked liver fibrosis will progress to cirrhosis an advanced stage of the disease estimated to affect of the wor ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  9. Generation of antibodies to monitor Notch O-fucosylation in vivo

    SBC: GlycoScientific, L.L.C.            Topic: 300

    Project Summary Notch is a cell surface protein that has diverse roles in human biology at all stages of life Notch is modified by a number of sugar structures including a number that are termed O fucose Alteration of the pattern of O fucose structures found on Notch has significant effects on Notch function which in turn has been linked to both developmental and adult pathologies includ ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  10. Proteasome inhibitor re-sensitizing molecules for treatment of refractory multiple myeloma

    SBC: Leukogene Therapeutics Inc.            Topic: 102

    Project Summary Abstract Multiple Myeloma MM is the second most common form of blood cancer and remains an incurable and deadly disease Proteasome inhibitor PI therapy is a cornerstone in the treatment of MM but resistance to this class of agent is an emerging challenge in the clinic New therapeutic approaches that specifically target resistance are needed to maximize responses and ultimate ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government